Injection device

ABSTRACT

An injection device comprising: a housing arranged to contain a liquid medicament or a medicament cartridge; an electrical coil arranged around an inner surface or an outer surface of the housing; an electricity storage apparatus electrically connected to the electrical coil; and a magnet arranged to be movable axially within a defined space with respect to the electrical coil, such that electrical voltage is induced in the electrical coil and a current is generated to charge the electricity storage apparatus.

TECHNICAL FIELD

The present disclosure relates to an injection device.

BACKGROUND

Current therapies delivered by means of self-administered injectionsinclude drugs for diabetes (both insulin and new GLP-A class drugs),migraine, hormone therapies, anticoagulants etc. Administering aninjection is a process which presents a number of risks and challengesfor user and healthcare professionals, both mental and physical.

Conventional injection devices typically fall under twocategories—manual devices and auto-injectors. In a conventional manualdevice, a user must provide a force to drive a liquid medicament out ofthe device, e.g. by depressing a plunger.

Auto-injectors aim to make self-administration of injected therapieseasier for users. Auto-injectors are devices which completely orpartially replace activities involved in medicament delivery of manualdevices. These activities may include removal of a protective syringecap, insertion of a needle into a patient's skin, injection of themedicament, removal of the needle, shield of the needle and preventingreuse of the device. This overcomes many of the disadvantages of manualdevices. Injection forces/button extension, hand-shaking and thelikelihood of delivering an incomplete dose are reduced. Triggering maybe performed by numerous means, for example a trigger button or theaction of the needle reaching its injection depth.

Some of the manual devices and auto-injectors are provided with on-boardequipment including light-emitting diodes and RFID tracking apparatus.In some of these devices with on-board equipment, batteries are providedso as to power the on-board equipment. However, these devices are oftenstored for a relatively long time before being used for injection. Aproblem is that, during this time of storage, battery corrosion andleakage may occur.

SUMMARY

According to an aspect of the present disclosure, there is provided aninjection device comprising: a housing arranged to contain a liquidmedicament or a medicament cartridge; an electrical coil arranged aroundan inner surface or an outer surface of the housing; an electricitystorage apparatus electrically connected to the electrical coil; aremovable cap that is arranged to be releasably attached to the housing;and a magnet arranged to be movable axially within a defined space withrespect to the electrical coil, such that electrical voltage is inducedin the electrical coil and a current is generated to charge theelectricity storage apparatus.

When a user shakes the injection device, the magnet moves within thedefined space and induces an electrical voltage in the electrical coil.At the same time, liquid medicament contained in the housing or themedicament cartridge is agitated by the shaking. Hence, the injectiondevice is more user-friendly and efficient to use, since it does notrequire extra operation steps for electricity generation.

The magnet may be fixed radially within the defined space.

The electricity storage apparatus may comprise a capacitor.

The injection device may comprise a RFID transducer configured to bepowered by the energy storage apparatus. The RFID transducer may be usedfor encoding certain medical information which allows the injectiondevice to be identified.

The injection device may comprise a solar cell arranged on the outersurface of the injection device, wherein electrical current generated bythe solar cell is stored in at least one of the electricity storageapparatus and an additional electricity storage apparatus. This providesan extra alternative way for electricity generation, which ensures theon-board equipment of the injection device can be properly powered.

The injection device may further comprise an electromagnetic lockingmechanism, the electromagnetic locking mechanism comprising a firstelectromagnet supported at the removable cap and a second electromagnetthat is arranged at the housing at a proximal end, the firstelectromagnet and second electromagnet being magnetically attached in aninitial state, wherein upon an activation of the electromagnetic lockingmechanism the first electromagnet and the second electromagnet arereleased such that the removable cap is detachable from the housing.

The injection device may further comprise an infrared LED light sourcearranged to emit a light beam to the liquid medicament or medicamentcartridge, a photo sensor arranged to receive reflected light fromparticles present in the medicament, and a control unit arranged tocalculate a turbidity of the medicament based on the received reflectedlight, wherein when the calculated turbidity reaches a predeterminedthreshold value, the electromagnetic locking mechanism is activated.

The electromagnetic locking mechanism may be activated when storedenergy in the energy storage apparatus reaches a predetermined thresholdvalue.

The injection device may further comprise: a first light source and asecond light source arranged on the outer surface of the injectiondevice, and a switching unit arranged to switch on the first lightsource when the electromagnetic locking mechanism is activated, and toswitch off the first light source and switch on the second light sourcewhen it is determined that all liquid medicament has been displaced fromthe injection device.

The housing may contain liquid medicament or a medicament cartridge.

The injection device may include a medicament.

The medicament may comprise injectable insulin.

According to another aspect of the present disclosure, there is provideda method of generating an electrical voltage at an injection device,comprising the steps of causing a magnet to move axially within adefined space in the injection device with respect to an electrical coilsuch that electrical voltage is induced in the electrical coil.

These and other aspects of the disclosure will be apparent from andelucidated with reference to the embodiments described hereinafter.

BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the disclosure will now be described, by way of exampleonly, with reference to the accompanying drawings, in which:

FIGS. 1A and 1B are side-on views of an auto-injection device accordingto an embodiment of the present disclosure;

FIG. 2 is a cross-sectional view of an injection device according to afirst embodiment of the present disclosure; and

FIG. 3 is another cross-section view of the injection device of FIG. 2;and

FIG. 4 is a perspective view of the injection device of FIGS. 2 and 3.

Reference will now be made in detail to the embodiments, examples ofwhich are illustrated in the accompanying drawings, wherein likereference numerals refer to like elements throughout.

DETAILED DESCRIPTION

An injection device with a system for harvesting energy is provided. Theinjection device comprises a housing for containing a liquid medicamentor a medicament cartridge, an electrical coil, an electricity storageapparatus, and a magnet. The electrical coil is arranged around an inneror outer surface of a housing of the injection device and the magnet isarranged to be movable axially with respect to the electrical coilwithin a defined space.

The magnet is configured to be moveable axially with respect to theelectrical coil when the injector device is shaken, such that electricalvoltage is induced in the electrical coil and a current is generated tocharge the electricity storage apparatus.

A drug delivery device, as described herein, may be configured to injecta medicament into a patient. For example, delivery could besub-cutaneous, intra-muscular, or intravenous. Such a device could beoperated by a patient or care-giver, such as a nurse or physician, andcan include various types of safety syringe, pen-injector, orauto-injector. The device can include a cartridge-based system thatrequires piercing a sealed ampule before use. Volumes of medicamentdelivered with these various devices can range from about 0.5 ml toabout 2 ml. Yet another device can include a large volume device (“LVD”)or patch pump, configured to adhere to a patient's skin for a period oftime (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large”volume of medicament (typically about 2 ml to about 10 ml).

In combination with a specific medicament, the presently describeddevices may also be customized in order to operate within requiredspecifications. For example, the device may be customized to inject amedicament within a certain time period (e.g., about 3 to about 20seconds for auto-injectors, and about 10 minutes to about 60 minutes foran LVD). Other specifications can include a low or minimal level ofdiscomfort, or to certain conditions related to human factors,shelf-life, expiry, biocompatibility, environmental considerations, etc.Such variations can arise due to various factors, such as, for example,a drug ranging in viscosity from about 3 cP to about 50 cP.Consequently, a drug delivery device will often include a hollow needleranging from about 25 to about 31 Gauge in size. Common sizes are 27 and29 Gauge.

The delivery devices described herein can also include one or moreautomated functions. For example, one or more of needle insertion,medicament injection, and needle retraction can be automated. Energy forone or more automation steps can be provided by one or more energysources. Energy sources can include, for example, mechanical, pneumatic,chemical, or electrical energy. For example, mechanical energy sourcescan include springs, levers, elastomers, or other mechanical mechanismsto store or release energy. One or more energy sources can be combinedinto a single device. Devices can further include gears, valves, orother mechanisms to convert energy into movement of one or morecomponents of a device.

The one or more automated functions of an auto-injector may each beactivated via an activation mechanism. Such an activation mechanism caninclude one or more of a button, a lever, a needle sleeve, or otheractivation component. Activation of an automated function may be aone-step or multi-step process. That is, a user may need to activate oneor more activation components in order to cause the automated function.For example, in a one-step process, a user may depress a needle sleeveagainst their body in order to cause injection of a medicament. Otherdevices may require a multi-step activation of an automated function.For example, a user may be required to depress a button and retract aneedle shield in order to cause injection.

In addition, activation of one automated function may activate one ormore subsequent automated functions, thereby forming an activationsequence. For example, activation of a first automated function mayactivate at least two of needle insertion, medicament injection, andneedle retraction. Some devices may also require a specific sequence ofsteps to cause the one or more automated functions to occur. Otherdevices may operate with a sequence of independent steps.

Some delivery devices can include one or more functions of a safetysyringe, pen-injector, or auto-injector. For example, a delivery devicecould include a mechanical energy source configured to automaticallyinject a medicament (as typically found in an auto-injector) and a dosesetting mechanism (as typically found in a pen-injector). According tosome embodiments of the present disclosure, an exemplary drug deliverydevice 10 is shown in FIGS. 1A & 1B. Device 10, as described above, isconfigured to inject a medicament into a patient's body. Device 10includes a housing 11 which typically contains a reservoir containingthe medicament to be injected (e.g., a syringe) and the componentsrequired to facilitate one or more steps of the delivery process. Device10 can also include a cap assembly 12 that can be detachably mounted tothe housing 11. In some implementations, a user may be required toremove cap 12 from housing 11 before device 10 can be operated.

As shown, housing 11 is substantially cylindrical and has asubstantially constant diameter along the longitudinal axis X. Thehousing 11 has a distal region 20 and a proximal region 21. The term“distal” refers to a location that is relatively closer to a site ofinjection, and the term “proximal” refers to a location that isrelatively further away from the injection site.

Device 10 can also include a needle sleeve 13 coupled to housing 11 topermit movement of sleeve 13 relative to housing 11. For example, sleeve13 can move in a longitudinal direction parallel to longitudinal axis X.Specifically, movement of sleeve 13 in a proximal direction can permit aneedle 17 to extend from distal region 20 of housing 11.

Insertion of needle 17 can occur via several mechanisms. For example,needle 17 may be fixedly located relative to housing 11 and initially belocated within an extended needle sleeve 13. Proximal movement of sleeve13 by placing a distal end of sleeve 13 against a patient's body andmoving housing 11 in a distal direction will uncover the distal end ofneedle 17. Such relative movement allows the distal end of needle 17 toextend into the patient's body. Such insertion termed “manual” insertionas needle 17 is manually inserted via the patient's manual movement ofhousing 11 relative to sleeve 13.

Another form of insertion is “automated,” whereby needle 17 movesrelative to housing 11. Such insertion can be triggered by movement ofsleeve 13 or by another form of activation, such as, for example, abutton 22. As shown in FIGS. 1A & 1 B, button 22 is located at aproximal end of housing 11. However, in other embodiments, button 22could be located on a side of housing 11.

Other manual or automated features can include drug injection or needleretraction, or both. Injection is the process by which a bung or piston23 is moved from a proximal location within a syringe (not shown) to amore distal location within the syringe in order to force a medicamentfrom the syringe through needle 17. In some embodiments, a drive spring(not shown) is under compression before device 10 is activated. Aproximal end of the drive spring can be fixed within proximal region 21of housing 11, and a distal end of the drive spring can be configured toapply a compressive force to a proximal surface of piston 23. Followingactivation, at least part of the energy stored in the drive spring canbe applied to the proximal surface of piston 23. This compressive forcecan act on piston 23 to move it in a distal direction. Such distalmovement acts to compress the liquid medicament within the syringe,forcing it out of needle 17.

Following injection, needle 17 can be retracted within sleeve 13 orhousing 11. Retraction can occur when sleeve 13 moves distally as a userremoves device 10 from a patient's body. This can occur as needle 17remains fixedly located relative to housing 11. Once a distal end ofsleeve 13 has moved past a distal end of needle 17, and needle 17 iscovered, sleeve 13 can be locked. Such locking can include locking anyproximal movement of sleeve 13 relative to housing 11.

Another form of needle retraction can occur if needle 17 is movedrelative to housing 11. Such movement can occur if the syringe withinhousing 11 is moved in a proximal direction relative to housing 11. Thisproximal movement can be achieved by using a retraction spring (notshown), located in distal region 20. A compressed retraction spring,when activated, can supply sufficient force to the syringe to move it ina proximal direction. Following sufficient retraction, any relativemovement between needle 17 and housing 11 can be locked with a lockingmechanism. In addition, button 22 or other components of device 10 canbe locked as required.

FIG. 2 is a cross-sectional view of an injector or injection deviceaccording to a first embodiment.

FIG. 2 shows an injection device 10 comprising a body 19, a removablecap 12, a housing 11, a piston, stopper or bung 14, an injection needle17, a syringe 18, an electrical coil 31, a magnet 32, a needle shield24, an electricity storage apparatus 25, a first light-emitting diode(LED) light source 26 a and a second LED light source 26 b, a solar cell27, and a switching unit 28. In this embodiment, the needle shield 24 isfixedly attached to the removable cap 12.

The housing 11 is arranged to contain a liquid medicament or amedicament cartridge. In the present embodiment, the housing 11comprises an outlet orifice, and is arranged to contain a medicamentcartridge in the form of a syringe 18. The housing 11 is generallyconsidered as being fixed in position so motion of other components isdescribed relative to the housing 11. In the present embodiment thesyringe 18, e.g. a refillable syringe, comprises a hollow injectionneedle 17 at its outlet orifice. The syringe 18 contains liquidmedicament which is to be delivered to a patient during injection.

When the injection device 10 is fully assembled (i.e. when the removablecap 12 is engaged with the housing 11), the needle shield 24 shields theoutlet orifice of the syringe 18 and acts as a needle shield to coverthe hollow injection needle 17. This keeps the needle sterile andprevents both damage to the needle during assembly and handling andaccess of a user to the needle for avoiding stick injuries.

The piston 23 is arranged for sealing the syringe 18 distally and fordisplacing a liquid medicament 16 through the hollow needle 17. Thepiston 23 in the present embodiment comprises a magnetic coating. Thesyringe 18 is held in the housing 11 and supported at its proximal endtherein.

An electrical coil 31 is arranged on an outer surface of the housing 11as shown in the drawing. As will be explained further with respect toFIG. 3, the electrical coil 31 comprises a first end and a second end,the first end being closer to the distal end of the injection device 10and the second bend being further away from the distal end of theinjection device 10.

In this embodiment, the magnet 32 has a cylindrical shape such that itcan be contained in a defined space 21 in a wall of the housing 11,which also has a cylindrical shape. FIG. 2 shows two cross-sections ofthe magnet 32 arranged around the inner surface of the housing 11 andcontained in the defined space 21. In this embodiment, the magnet 32 isfixed radially with respect to the rest of the injection device 10 suchthat it is configured to move only in a direction parallel to the axisof the injection device 10.

In this embodiment, the electrical coil 31 is arranged at a positionnear to the proximal end of the housing 11. Specifically, the electricalcoil 31 is arranged such that it surrounds the defined space 21 in thewall of the housing 11 in which the magnet 32 is contained. The definedspace 21 provides axial guidance for the motion of the magnet 32 whenthe injection device 10 is shaken. When the injection device 10 isshaken by a user, the magnet 32 is arranged to move linearly withrespect to the electrical coil 31 within the defined space 21 from oneend to another. This particular configuration provides an increasedeffectiveness of the generation of electrical voltage in the electricalcoil 31, since the magnet 32 is always moving within the electrical coil31.

In more detail, when a user shakes the injection device 10, the magnet32 is free to move from one end of the defined space 21 to another. Themovement of the magnet 32 relative to the electrical coil 31 induces anelectrical voltage in the electrical coil 31. An electrical current isgenerated in the electrical coil 31 which is used to charge the energystorage apparatus 25. The energy storage apparatus 25 in the presentembodiment comprises a capacitor, but it may comprise another componentsuch as a rechargeable battery cell.

The injection device 10 further comprises an electromagnetic lockingmechanism (not shown in the drawing) that is arranged to allow theremovable cap 12 to be detached from the housing 11 only after theinjection device 10 has been sufficiently shaken.

The electromagnetic locking mechanism is electrically connected to theelectricity storage apparatus 25, and comprises a first electromagnet(not shown in the drawing) that is supported at the removable cap 12 anda second electromagnet (not shown in the drawing) that is arranged atthe proximal end of the housing 11. In an initial state, i.e. when theremovable cap 12 is attached to the housing 11, the first electromagnetand the second electromagnet are magnetically attached to each other,such that the user cannot detach the removable cap 12 from the housing11.

Only after the user shakes the injection device 10 sufficiently, theelectromagnetic locking mechanism is activated, causing the first andsecond electromagnets to be released such that the user can detach theremovable cap 12 from the housing 11. In the present embodiment, theinjection device 10 further comprises a turbidity measuring system so asto measure a turbidity of the liquid medicament contained in the syringe18. If the measured turbidity of the liquid medicament reaches apredetermined threshold value, the electromagnetic locking mechanismactivation is triggered to release the first and second electromagnets.The operation of the turbidity measuring system will be explained infurther detail with respect to FIG. 4.

The first and second LED light sources 26 a and 26 b can be powered bythe energy stored in the energy storage apparatus 25. In thisembodiment, the first LED light source 26 a is a green LED light sourceand the second LED light source is a red LED light source. The first LEDlight source 26 a is arranged such that it is switched on when theelectromagnetic locking mechanism is activated, i.e. when the firstelectromagnet and the second electromagnet are released so as to allowthe removable cap 12 to be detached from the housing 11. In the presentembodiment, as the electromagnetic locking mechanism is activated, thefirst LED light source 26 a flashes green. This provides an indicationto the user that the injection device 10 is now ready for use.

A switching unit 28 is provided at the injection device 10 so as toswitch off the first LED light source 26 a and switch on the second LEDlight source 26 b, when it is detected that the piston 23 has reached anend of the syringe 18. This indicates that all liquid medicament in thesyringe 18 has been displaced from the syringe 18.

As described above, the piston 23 in the present embodiment is providedwith a magnetic coating so as to allow the switching unit 28 todetermine when it has reached the end of the syringe 18 during aninjection. In the present embodiment, when the piston 23 has reached theend of the syringe 18, the switching unit 28 is activated by the piston23 such that it switches off the first LED light source 26 a andswitches on the second LED light source 26 b. The second LED lightsource 26 b flashes red to indicate to the user that the injectiondevice 10 has been used and can now be discarded.

In the present embodiment, a solar cell 27 is arranged on the outersurface of the housing 11 and the body 19 for generating extraelectricity for powering the LED light sources 26 a and 26 b and otheron-board equipment that is not illustrated in FIG. 2. The solar cell 27is considered as a further power source in addition to the arrangementof the electrical coil 31 and the magnet 32.

Another cross-sectional view is provided in FIG. 2 which shows thehousing 11, the removable cap 12, the magnet 32, and the needle shield24 as viewed from the proximal end of the injection device 10.

FIG. 3 is another cross-section view of the injection device of FIG. 2.

FIG. 3 illustrate directions of motion of the magnet 32 when theinjector device 10 is shaken by a user. These are represented by thedouble-headed arrows between the electrical coil 31 and the needleshield 24.

FIG. 3 also shows the a direction of the force F applied to the magnet32 as the magnet 32 is being moved from the first end 31 a to the secondend 31 b of the electrical coil, a direction of the magnetic field B ofthe magnet 32, and a resultant direction of the current I (out of thepage) generated when the magnet 32 moves from a first end 31 a of theelectrical coil 31 to a second end 31 b of the electrical coil 31. Thefirst end 31 a of the electrical coil 31 is closer to a distal end ofthe housing 11 and the second end 31 b of the electrical coil 31 isfurther away from the distal end of the housing 11.

As described above, the magnet 32 moves linearly with respect to theelectrical coil 31 as the injection device 10 is being shaken by a user.An electrical current is induced in the electrical coil 31 in directionsso as to produce forces opposing the motion. The induced current is usedto charge the energy storage apparatus 25 (not shown in this drawing),such that it can power on-board equipment of the injection device 10.

FIG. 4 is a perspective view of the injection device of FIGS. 2 and 3.

The exterior of the injection device 10 is illustrated in FIG. 4. Asshown in the drawing, the injection device 10 comprises a body 19, aremovable cap 12, a housing 11, the LED light sources 26 a and 26 b, asolar cell 27, a switching unit 28, a photo sensor 29, and an infraredLED light source 30.

The operation and arrangement of the body 19, the removable cap 12, thehousing 11, the LED light sources 26 a and 26 b, the solar cell 27, andthe switching unit 28 are as described with respect to the previousdrawings.

The turbidity measuring system of the present embodiment comprises thephoto sensor 29, the infrared LED light source 30, and a control unit(not shown in the drawing). The infrared LED light source 30 is arrangedto emit a beam towards the syringe 18 containing the liquid medicament,and the photo sensor 29 is arranged at a position at an angle of 90°from a path of the emitted beam of the infrared LED light source 30. Theemitted light beam from the infrared LED light source 30 is reflectedoff particles present in the liquid medicament, and a portion of thelight beam is reflected towards the photo sensor 29. The photo sensor 29is arranged to receive light reflected from the particles present in theliquid medicament in the syringe 18 for the calculation of turbidity ofthe liquid medicament in the syringe 18.

The control unit (not shown in the drawing) is provided so as tocalculate the turbidity of the liquid medicament in NephelometricTurbidity Units (NTU). As described above, the calculated turbidity isused for the activation of the electromagnetic locking mechanism. Oncethe calculated turbidity of the liquid medicament reaches thepredetermined threshold value, the electromagnetic locking mechanismactivation is triggered to release the first and second electromagnetswhich are respectively arranged at the removable cap 12 and the proximalend of the housing 11. Therefore, the first electromagnet is no longermagnetically attached to the second electromagnet and the user can nowdetach the removable cap 12 from the housing 11.

A sequence of operation of the injection device 10 according to thesecond embodiment is as follows:

A user shakes the injection device 10, causing the magnet 32 that iscontained within the space defined in the wall of the housing 11 to moveforwards and backwards, i.e. axially and linearly with respect to theelectrical coil 31. The movement of the magnet 32 with respect of theelectrical coil 31 causes a change in magnetic field around theelectrical coil 31.

This generates an electrical voltage in the electrical coil 31 and anelectrical current, which is used to charge the energy storage apparatus25. The electricity stored at the energy storage apparatus 25 would thenbe used to power any on-board equipment of the injection device 10,which includes the first and second LED light sources 26 a and 26 b andRFID tracking apparatus (not shown in the drawing).

The turbidity measuring system measures the turbidity of the liquidmedicament contained in the syringe 18. Specifically, the infrared LEDlight source 30 emits a light beam towards the syringe 18, the photosensor 29 measures reflected light from particles present in the liquidmedicament in the syringe, and the control unit calculates the turbidityof the liquid medicament. Once the turbidity of the liquid medicamentreaches the predetermined threshold value, the electromagnetic lockingmechanism activation is triggered to release the first and secondelectromagnets which are respectively arranged at the removable cap 12and the proximal end of the housing 11. Therefore, the firstelectromagnet is no longer magnetically attached to the secondelectromagnet and the user can now detach the removable cap 12 from thehousing 11. At the same time, the first LED light source 26 a flashesgreen upon the activation of the electromagnetic locking mechanism, inorder to indicate that the first electromagnet is released from thesecond electromagnet.

The user pulls off the removable cap 12 from the proximal end of thehousing 11, which causes the removable cap 12 to be disengaged from thehousing 11. Since the needle shield 24 is arranged at the removable cap12, when the removable cap 12 is disengaged from the housing 11 theneedle shield 24 is also removed together with the removable cap 12,such that the hollow injection needle 17 is exposed at the outletorifice of the housing 11, ready for injection.

In order to trigger an injection, the injection device 10 is pressedagainst an injection site, e.g. a patient's skin. A user, e.g. thepatient or a caregiver, grabs the injection device 10 with their wholehand and pushes the proximal end of the injection 10 against theinjection site.

After the needle 17 has been inserted into the injection site, a plungerarrangement (not shown in the drawings) is activated to push the piston23, which in turns pushes the liquid medicament contained in the syringe18 through the needle 17 into the injection site of the patient.

When the piston 23 reaches an end of the syringe, i.e. when all theliquid medicament contained in the syringe 18 has been displaced, theswitching unit 28 detects the presence of the magnetic coating of thepiston 23 and activates such that it switches off the first LED lightsource 26 a and switches on the second LED light source 26 b. The secondLED light source 26 b flashes red to indicate to the user that theinjection device 10 has been used and can now be discarded.

The injection device 10 according to this embodiment provides atechnical advantage that, when used with a liquid medicament thatrequires a period of shaking prior of administration in order to agitatethe medicament, e.g. insulin, the shaking of the injection device 10simultaneously generate electrical energy for powering the on-boardequipment (e.g. LEDs and RFID tracking apparatus) of the injectiondevice and agitate the drug appropriately prior to delivery to thepatient. This makes the injection device 10 more user-friendly andefficient to use, since it does not require extra operation steps forelectricity generation. The electromagnetic locking mechanism ensuresthat the liquid medicament has been shaken sufficiently immediatelyprior to injection.

Although in some described embodiments, the injection device is anauto-injection device, in alternative embodiments the injection devicemay be a manual device in which injection is manually driven.

Although it is described above that the electrical coil is arranged onthe outer surface of the housing, in alternative embodiments theelectrical coil may be arranged on the inner surface of the housing soas to reduce the amount of electrical loss due to the material betweenthe inner and outer surfaces of the housing.

In alternative embodiments, the first and second LED light sources mayhave different colours instead of red and green.

In alternative embodiments, the injection device may not comprise anelectromagnetic locking mechanism as described above.

In alternative embodiments, the injection device may not comprise aturbidity measurement system as described above. In such embodiments,the electromagnetic locking mechanism may be directly powered by thecurrent generated at the electrical coil, instead of powered by storedenergy in the energy storage apparatus. For example, the electromagneticlocking mechanism may be activated when the energy stored in the energystorage apparatus reaches a predetermined threshold value.

In alternative embodiments, the magnet may be arranged such that,instead of being located within a space defined between the innersurface of the housing and the tubular member, it is located within adefined space in a wall of the removable cap. In such alternativeembodiments, the removable cap is to be kept attached to the housing ofthe injection device when the user shakes the injection device, in orderto generate electrical voltage in the electrical coil.

Although it is described above that the needle shield is fixedlyattached to the removable cap, in alternative embodiments the needleshield is not fixed to the removable cap. In these alternativeembodiments, after detaching the removable cap the user is required tomanually remove the needle shield in order to expose the injectionneedle ready for injection.

In alternative embodiments, other known materials and forms for solarcell may be used for the solar cell.

In alternative embodiments, the magnet may not be fixed radially withrespect to the rest of the injection device. In such alternativeembodiments, the movement of the magnet with respect to the electricalcoil may be achieved by e.g. a swirling motion of the injection device.In such embodiments, the positioning and configuration of the electricalcoil may be different so as to adapt to the movement of the magnet foreffective electricity generation.

In alternative embodiments, other electrical storage apparatus may beused instead of a capacitor.

In alternative embodiments, other light sources may be used in theinjection device instead of LED light sources.

In alternative embodiments, the first and second LED light sources maybe replaced by a single RGB LED light source. In such embodiments, thesingle RGB LED light source may be arranged to emit a first colour (e.g.green) when the electromagnetic locking mechanism is activated, and theswitching unit may be arranged to control the single RGB LED to emit asecond colour (e.g. red) when it is detected that the piston has reachedan end of the syringe.

In alternative embodiments, the first and second LED light sources maybe replaced by a single LED light source and colour foil.

In alternative embodiments, the hollow injection needle may be replacedby other discharging or injection mechanisms. For example, the outletorifice may be configured to be a discharge orifice so that an injectionneedle is not required. As another example, a nozzle may be provided atthe outlet orifice of the syringe for discharge of liquid medicament.

In alternative embodiments, the electromagnetic locking mechanismactivation is triggered by other techniques. For example, theelectromagnetic locking mechanism may be activated when the energystored in the energy storing apparatus 25 reaches a predeterminedthreshold value.

Although it is shown in the drawings that a single magnet is used in theinjection device, in alternative embodiments a plurality of magnets maybe used. In such embodiments, the plurality of magnets may have asimilar arrangement to that of the embodiment as described, i.e. beingconfigured to move linearly with respect to the electrical coil arrangedat the housing of the injection device, and being fixed radially andconfigured to move in a direction parallel to the axis of the injectiondevice.

Although claims have been formulated in this application to particularcombinations of features, it should be understood that the scope of thedisclosure also includes any novel features or any novel combinations offeatures disclosed herein either explicitly or implicitly or anygeneralisation thereof, whether or not it relates to the same disclosureas presently claimed in any claim and whether or not it mitigates any orall of the same technical problems as does the present disclosure. Theapplicant hereby gives notice that new claims may be formulated to suchfeatures and/or combinations of features during the prosecution of thepresent application or of any further application derived therefrom.

Although a few embodiments have been shown and described, it would beappreciated by those skilled in the art that changes may be made inthese embodiments without departing from the principles of thedisclosure, the scope of which is defined in the claims.

The terms “drug” or “medicament” are used synonymously herein anddescribe a pharmaceutical formulation containing one or more activepharmaceutical ingredients or pharmaceutically acceptable salts orsolvates thereof, and optionally a pharmaceutically acceptable carrier.An active pharmaceutical ingredient (“API”), in the broadest terms, is achemical structure that has a biological effect on humans or animals. Inpharmacology, a drug or medicament is used in the treatment, cure,prevention, or diagnosis of disease or used to otherwise enhancephysical or mental well-being. A drug or medicament may be used for alimited duration, or on a regular basis for chronic disorders.

As described below, a drug or medicament can include at least one API,or combinations thereof, in various types of formulations, for thetreatment of one or more diseases. Examples of API may include smallmolecules having a molecular weight of 500 Da or less; polypeptides,peptides and proteins (e.g., hormones, growth factors, antibodies,antibody fragments, and enzymes); carbohydrates and polysaccharides; andnucleic acids, double or single stranded DNA (including naked and cDNA),RNA, antisense nucleic acids such as antisense DNA and RNA, smallinterfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleicacids may be incorporated into molecular delivery systems such asvectors, plasmids, or liposomes. Mixtures of one or more drugs are alsocontemplated.

The term “drug delivery device” shall encompass any type of device orsystem configured to dispense a drug or medicament into a human oranimal body. Without limitation, a drug delivery device may be aninjection device (e.g., syringe, pen injector, auto injector,large-volume device, pump, perfusion system, or other device configuredfor intraocular, subcutaneous, intramuscular, or intravasculardelivery), skin patch (e.g., osmotic, chemical, micro-needle), inhaler(e.g., nasal or pulmonary), an implantable device (e.g., drug- orAPI-coated stent, capsule), or a feeding system for thegastro-intestinal tract. The presently described drugs may beparticularly useful with injection devices that include a needle, e.g.,a hypodermic needle for example having a Gauge number of 24 or higher.

The drug or medicament may be contained in a primary package or “drugcontainer” adapted for use with a drug delivery device. The drugcontainer may be, e.g., a cartridge, syringe, reservoir, or other solidor flexible vessel configured to provide a suitable chamber for storage(e.g., short- or long-term storage) of one or more drugs.

For example, in some instances, the chamber may be designed to store adrug for at least one day (e.g., 1 to at least 30 days). In someinstances, the chamber may be designed to store a drug for about 1 monthto about 2 years. Storage may occur at room temperature (e.g., about 20°C.), or refrigerated temperatures (e.g., from about −4° C. to about 4°C.). In some instances, the drug container may be or may include adual-chamber cartridge configured to store two or more components of thepharmaceutical formulation to-be-administered (e.g., an API and adiluent, or two different drugs) separately, one in each chamber. Insuch instances, the two chambers of the dual-chamber cartridge may beconfigured to allow mixing between the two or more components prior toand/or during dispensing into the human or animal body. For example, thetwo chambers may be configured such that they are in fluid communicationwith each other (e.g., by way of a conduit between the two chambers) andallow mixing of the two components when desired by a user prior todispensing. Alternatively or in addition, the two chambers may beconfigured to allow mixing as the components are being dispensed intothe human or animal body.

The drugs or medicaments contained in the drug delivery devices asdescribed herein can be used for the treatment and/or prophylaxis ofmany different types of medical disorders. Examples of disordersinclude, e.g., diabetes mellitus or complications associated withdiabetes mellitus such as diabetic retinopathy, thromboembolismdisorders such as deep vein or pulmonary thromboembolism. Furtherexamples of disorders are acute coronary syndrome (ACS), angina,myocardial infarction, cancer, macular degeneration, inflammation, hayfever, atherosclerosis and/or rheumatoid arthritis. Examples of APIs anddrugs are those as described in handbooks such as Rote Liste 2014, forexample, without limitation, main groups 12 (anti-diabetic drugs) or 86(oncology drugs), and Merck Index, 15th edition.

Examples of APIs for the treatment and/or prophylaxis of type 1 or type2 diabetes mellitus or complications associated with type 1 or type 2diabetes mellitus include an insulin, e.g., human insulin, or a humaninsulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1analogues or GLP-1 receptor agonists, or an analogue or derivativethereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or apharmaceutically acceptable salt or solvate thereof, or any mixturethereof. As used herein, the terms “analogue” and “derivative” refer toany substance which is sufficiently structurally similar to the originalsubstance so as to have substantially similar functionality or activity(e.g., therapeutic effectiveness). In particular, the term “analogue”refers to a polypeptide which has a molecular structure which formallycan be derived from the structure of a naturally occurring peptide, forexample that of human insulin, by deleting and/or exchanging at leastone amino acid residue occurring in the naturally occurring peptideand/or by adding at least one amino acid residue. The added and/orexchanged amino acid residue can either be codable amino acid residuesor other naturally occurring residues or purely synthetic amino acidresidues. Insulin analogues are also referred to as “insulin receptorligands”. In particular, the term “derivative” refers to a polypeptidewhich has a molecular structure which formally can be derived from thestructure of a naturally occurring peptide, for example that of humaninsulin, in which one or more organic substituent (e.g. a fatty acid) isbound to one or more of the amino acids. Optionally, one or more aminoacids occurring in the naturally occurring peptide may have been deletedand/or replaced by other amino acids, including non-codeable aminoacids, or amino acids, including non-codeable, have been added to thenaturally occurring peptide.

Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) humaninsulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulinglulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28)human insulin (insulin aspart); human insulin, wherein proline inposition B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein inposition B29 Lys may be replaced by Pro; Ala(B26) human insulin;Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) humaninsulin.

Examples of insulin derivatives are, for example,B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®);B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin;B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 humaninsulin; B28-N-palmitoyl-LysB28ProB29 human insulin;B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) humaninsulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30)human insulin (insulin degludec, Tresiba®);B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin;B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin andB29-N-(ω-carboxyhepta¬decanoyl) human insulin.

Examples of GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, forexample, Lixisenatide (Lyxumia®, Exenatide (Exendin-4, Byetta®,Bydureon®, a 39 amino acid peptide which is produced by the salivaryglands of the Gila monster), Liraglutide (Victoza®), Semaglutide,Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®),rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3,GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen,Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701,MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864,ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.

An example of an oligonucleotide is, for example: mipomersen sodium(Kynamro®), a cholesterol-reducing antisense therapeutic for thetreatment of familial hypercholesterolemia.

Examples of DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin,Saxagliptin, Berberine.

Examples of hormones include hypophysis hormones or hypothalamushormones or regulatory active peptides and their antagonists, such asGonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin),Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin,Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.

Examples of polysaccharides include a glucosaminoglycane, a hyaluronicacid, a heparin, a low molecular weight heparin or an ultra-lowmolecular weight heparin or a derivative thereof, or a sulphatedpolysaccharide, e.g. a poly-sulphated form of the above-mentionedpolysaccharides, and/or a pharmaceutically acceptable salt thereof. Anexample of a pharmaceutically acceptable salt of a poly-sulphated lowmolecular weight heparin is enoxaparin sodium. An example of ahyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodiumhyaluronate.

The term “antibody”, as used herein, refers to an immunoglobulinmolecule or an antigen-binding portion thereof. Examples ofantigen-binding portions of immunoglobulin molecules include F(ab) andF(ab')2 fragments, which retain the ability to bind antigens. Theantibody can be polyclonal, monoclonal, recombinant, chimeric,de-immunized or humanized, fully human, non-human, (e.g., murine), orsingle chain antibody. In some embodiments, the antibody has effectorfunction and can fix a complement. In some embodiments, the antibody hasreduced or no ability to bind an Fc receptor. For example, the antibodycan be an isotype or subtype, an antibody fragment or mutant, which doesnot support binding to an Fc receptor, e.g., it has a mutagenized ordeleted Fc receptor binding region. The term antibody also includes anantigen-binding molecule based on tetravalent bispecific tandemimmunoglobulins (TBTI) and/or a dual variable region antibody-likebinding protein having cross-over binding region orientation (CODV).

The terms “fragment” or “antibody fragment” refer to a polypeptidederived from an antibody polypeptide molecule (e.g., an antibody heavyand/or light chain polypeptide) that does not comprise a full-lengthantibody polypeptide, but that still comprises at least a portion of afull-length antibody polypeptide that is capable of binding to anantigen. Antibody fragments can comprise a cleaved portion of a fulllength antibody polypeptide, although the term is not limited to suchcleaved fragments. Antibody fragments that are useful in the presentdisclosure include, for example, Fab fragments, F(ab')2 fragments, scFv(single-chain Fv) fragments, linear antibodies, monospecific ormultispecific antibody fragments such as bispecific, trispecific,tetraspecific and multispecific antibodies (e.g., diabodies, triabodies,tetrabodies), monovalent or multivalent antibody fragments such asbivalent, trivalent, tetravalent and multivalent antibodies, minibodies,chelating recombinant antibodies, tribodies or bibodies, intrabodies,nanobodies, small modular immunopharmaceuticals (SMIP), binding-domainimmunoglobulin fusion proteins, camelized antibodies, and VHH containingantibodies. Additional examples of antigen-binding antibody fragmentsare known in the art.

The terms “Complementarity-determining region” or “CDR” refer to shortpolypeptide sequences within the variable region of both heavy and lightchain polypeptides that are primarily responsible for mediating specificantigen recognition. The term “framework region” refers to amino acidsequences within the variable region of both heavy and light chainpolypeptides that are not CDR sequences, and are primarily responsiblefor maintaining correct positioning of the CDR sequences to permitantigen binding. Although the framework regions themselves typically donot directly participate in antigen binding, as is known in the art,certain residues within the framework regions of certain antibodies candirectly participate in antigen binding or can affect the ability of oneor more amino acids in CDRs to interact with antigen. Examples ofantibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g.,Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).

Pharmaceutically acceptable salts of any API described herein are alsocontemplated for use in a drug or medicament in a drug delivery device.Pharmaceutically acceptable salts are for example acid addition saltsand basic salts.

Those of skill in the art will understand that modifications (additionsand/or removals) of various components of the APIs, formulations,apparatuses, methods, systems and embodiments described herein may bemade without departing from the full scope and spirit of the presentdisclosure, which encompass such modifications and any and allequivalents thereof.

The invention claimed is:
 1. An injection device comprising: a housingarranged to contain a liquid medicament or a medicament cartridge; anelectrical coil arranged around an inner surface or an outer surface ofthe housing; an electricity storage apparatus electrically connected tothe electrical coil; a removable cap that is arranged to be releasablyattached to the housing; and a magnet arranged to be movable axiallywithin a defined space with respect to the electrical coil, such thatelectrical voltage is induced in the electrical coil and a current isgenerated to charge the electricity storage apparatus, wherein thedefined space is arranged at a wall of the removable cap.
 2. Theinjection device of claim 1, wherein the magnet is fixed radially withinthe defined space.
 3. The injection device of claim 1, wherein theelectricity storage apparatus comprises a capacitor.
 4. The injectiondevice of claim 1, further comprising a RFID transducer configured to bepowered by the electricity storage apparatus.
 5. The injection device ofclaim 1, further comprising a solar cell arranged on the outer surfaceof the injection device, wherein electrical current generated by thesolar cell is stored in at least one of the electricity storageapparatus and/or an additional electricity storage apparatus.
 6. Theinjection device of claim 1, further comprising an electromagneticlocking mechanism, the electromagnetic locking mechanism comprising afirst electromagnet supported at the removable cap and a secondelectromagnet that is arranged at the housing at a proximal end, thefirst electromagnet and second electromagnet being magnetically attachedin an initial state, wherein upon an activation of the electromagneticlocking mechanism the first electromagnet and the second electromagnetare released such that the removable cap is detachable from the housing.7. The injection device of claim 6, further comprising an infrared LEDlight source arranged to emit a light beam to the liquid medicament ormedicament cartridge, a photo sensor arranged to receive reflected lightfrom particles present in the medicament, and a control unit arranged tocalculate a turbidity of the medicament based on the received reflectedlight, wherein when the calculated turbidity reaches a predeterminedthreshold value, the electromagnetic locking mechanism is activated. 8.The injection device of claim 6, wherein the electromagnetic lockingmechanism is activated when stored energy in the electricity storageapparatus reaches a predetermined threshold value.
 9. The injectiondevice of claim 6, further comprising: a first light source and a secondlight source arranged on the outer surface of the injection device, anda switching unit arranged to switch on the first light source when theelectromagnetic locking mechanism is activated, and to switch off thefirst light source and switch on the second light source when it isdetermined that all liquid medicament has been displaced from theinjection device.
 10. The injection device of claim 1, wherein thehousing contains liquid medicament or a medicament cartridge.
 11. Theinjection device of claim 1, wherein the device includes a medicament.12. The injection device of claim 11, wherein the medicament comprisesinjectable insulin.